ArticleThe Journal of biological chemistry2010
Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1.
Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies.Signal transduction and targeted therapy · 2024Review
- Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance.Scientific reports · 2022Article
- Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype.Stem cell reports · 2019Article
- Notch signaling activation induces cell death in MAPKi-resistant melanoma cells.Pigment cell & melanoma research · 2019Article
- Modulation of mitochondrial respiration underpins neuronal differentiation enhanced by lutein.Neural regeneration research · 2019Article
- Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study.Oncotarget · 2017Article
- Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.Melanoma research · 2017Article
- Anticancer properties of phospholipase A2 from Daboia siamensis venom on human skin melanoma cells.The journal of venomous animals and toxins including tropical diseases · 2016Article
- Neural fate decisions mediated by combinatorial regulation of Hes1 and miR-9.Journal of biological physics · 2016Article
- In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.Molecular cancer · 2015Article
- RAFting the rapids of axon regeneration signaling.Neural regeneration research · 2015Article
- NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition.Oncogenesis · 2013Article
- Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.Cancer research · 2013Article
- Cancer stem cells and tumor transdifferentiation: implications for novel therapeutic strategies.American journal of stem cells · 2013Article
- Restored expression of the atypical heat shock protein H11/HspB8 inhibits the growth of genetically diverse melanoma tumors through activation of novel TAK1-dependent death pathways.Cell death & disease · 2012Article
- The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells.Cell cycle (Georgetown, Tex.) · 2012Article
- Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells.Endocrine-related cancer · 2011Article
- Epigenetic regulation of the calcitonin gene-related peptide gene in trigeminal glia.Cephalalgia : an international journal of headache · 2011Article
- Forced notch signaling inhibits commissural axon outgrowth in the developing chick central nerve system.PloS one · 2011Article
- Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.Biochemical pharmacology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
MAP2 is a neuron-specific microtubule-associated protein that binds and stabilizes dendritic microtubules. Previously, we showed that MAP2 expression is (a) activated in cutaneous primary melanoma and (b) inversely associated with melanoma tumor progression. We also showed that ectopic expression of MAP2 in metastatic melanoma cells inhibits cell growth by inducing mitotic spindle defects and apoptosis. However, molecular mechanisms of regulation of MAP2 gene expression in melanoma are not understood. Here, we show that in melanoma cells MAP2 expression is induced by the demethylating agent 5-aza-2'-cytidine, and MAP2 promoter is progressively methylated during melanoma progression, indicating that epigenetic mechanisms are involved in silencing of MAP2 in melanoma. In support of this, methylation of MAP2 promoter DNA in vitro inhibits its activity. Because MAP2 promoter activity levels in melanoma cell lines also correlated with activating mutation in BRAF, a gene that is highly expressed in neurons, we hypothesized that BRAF signaling is involved in MAP2 expression. We show that hyperactivation of BRAF-MEK signaling activates MAP2 expression in melanoma cells by two independent mechanisms, promoter demethylation or down-regulation of neuronal transcription repressor HES1. Our data suggest that BRAF oncogene levels can regulate melanoma neuronal differentiation and tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.